Higher genetic risk for inflammatory bowel disease is linked to more severe disease and increased risks for hospital stays and earlier need for advanced treatments.

ON THIS PAGEWhy Urgency Happens in UCSolutions for UC UrgencyWhen Urgency Is a Bigger ProblemMore than80 percent of people with ulcerative colitis (UC) experience bowel urgency that overwhelming, need ...

ON THIS PAGESymptomsComplicationsWhy Fulminant Colitis OccursWhat to Do During a Severe UC FlareAfter a Fulminant UC EpisodeFor some people with ulcerative colitis (UC), the symptoms are mild. But for ...

A new ulcerative colitis diagnosis can feel overwhelming—but with thoughtful food choices, lifestyle strategies and ...

These easy weeknight-friendly dinner recipes are high in protein, heart-healthy, and avoid common trigger foods to help ...

Walking is a simple, lower-intensity option that may help reduce stress, which can benefit people with UC. “Lower-impact and ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...

Ulcerative colitis is a long-term disease that causes inflammation in the large intestine. It can lead to abdominal pain, diarrhea, bleeding, fatigue, and weight loss. For many people, the disease ...

When prescription prices keep climbing, patients are forced into impossible decisions — skipping doses, delaying treatment or choosing between medication and other basic needs. For people with Crohn’s ...

Johnson & Johnson today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through ...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 ...